Eric Greenwald focuses his practice on US and foreign patent portfolio management and strategic legal counseling for clients in the biotechnology industry. His counseling experience includes patentability and freedom to operate assessments, due diligence analyses, and review of IP provisions in support of filings before the SEC. Eric counsels research and academic institutions, startup companies, and mid-sized biotech companies. He has a deep background in gene therapy, genome editing, adoptive immunotherapy, engineered cell therapies, therapeutic antibodies, and DNA and peptide sequencing applications.
Eric also handles post-grant proceedings, including inter partes review (IPRs) and interference proceedings before the PTAB, as well as European opposition proceedings and USPTO third-party submissions. In addition, Eric handles review and revision of licensing agreements.
Prior to joining Wolf Greenfield, Eric was an associate at Axinn, Veltrop & Harkrider LLP. There, he represented clients in district court patent litigation and copyright litigation, PTAB proceedings, and food and drug law counseling.
Eric has a Certificate in Business Economics and Public Policy from the Wharton School at the University of Pennsylvania.
Ghosh, S., Greenwald, EP., (2018) Expert Q&A on Key Updates in BPCIA Litigation. Thomson Reuters Practice Law: Practice Law the Journal – Litigation. W-015-9057.